Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 2395840 in diabetic neuropathic pain
2021-001392-17Phase 2Completed
- Sponsor
- Bayer
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fulmetibant in diabetic polyneuropathy (DPN) (2 arms), sponsored by Bayer. Primary endpoint: Change in weekly mean 24-hour average pain intensity score. Started Oct 2021; status: completed.
02
Drugs
fulmetibant
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on 2021-001392-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001392-17.